ALK-Abelló A/S (ALK-B) fair value: what the stock is really worth
As of Oct 20, 2026: fair value (intrinsic value) of ALK-Abelló A/S stock DKK 250, price DKK 238, upside +5.1%, quality 77 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 14, 2026.
How to read this chart
60‑month range kr 70.27 – kr 270.40 · fair‑value band kr 183.75 – kr 312.40 · the kr 237.80 price screens below the kr 249.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 14, 2026.
Follow ALK-Abelló A/S in your weekly email
Every Wednesday you see whether ALK-Abelló A/S is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally.
Show moreShow less
The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies.
It also provides GRAZAX/GRASTEK, a tablet for grass pollen allergy; ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies; ITULAZAX/ITULATEK, a tablet for tree pollen allergy; RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy; and CEDARCURE, a tablet for Japanese cedar pollen allergy.
In addition, the company offers consumer healthcare solutions, such as klarify.me, a digital patient engagement platform to help people manage their allergies.
Further, it provides allergen extracts for use in the diagnosis of specific allergies, such as skin prick and blood test; and emergency medicine treatment, such as adrenaline autoinjectors, an intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis.
The company has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX and CEDARCURE; and Dr. Reddy's Laboratories for the development of Sensimune. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.
Stock analysis
ALK-Abelló A/S (ALK-B) currently trades at kr 237.80, while our model-based Fair Value estimate is kr 249.92, so the stock looks roughly fairly valued today (gap 4.8%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 151.20 per share, and 0 of the 26 models we run sit above the kr 237.80 price.
Bear case: the Economic Profit group reads lowest at kr 50.60, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: kr 183.75 (bear) to kr 312.40 (bull), the price of kr 237.80 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 77/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
ALK-Abelló A/S reported revenue of 6.3B DKK in FY2025 versus 3.9B DKK in FY2021, a compound +12.7%/yr. Reported net income was 1.2B DKK in FY2025, compounding +52.9%/yr from FY2021.
Key figures
Market cap 52.8B DKK (≈ $7.9B) Mid · P/E ratio 32.8 · P/S ratio 7.70 · EPS (TTM) kr 6.09 · Dividend yield 0.7% · Net margin 19.9% · Return on equity 21.2% · Return on assets (EBIT) 10.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 78 out of 100 (medium confidence).
What moves the price
The share trades about 12% below its 52-week high and 24% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 5%, ALK-B screens richer than that median.
Fair Value models
Bearkr 183.75Fair Value kr 249.92Bullkr 312.40
Price kr 237.80 · Upside +5.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 3.60 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.97/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+14.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
Start year 2020 (pandemic). Over 10 years: +9.4% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+56.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+55.9%
Dividend (yield on the price)0.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.57.8% vs 14.8%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 26%
2025 sits 146% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (Denmark: IMF forecast 2.1% a year to 2030, 2.0% from 2016 to 2025) that is about +14.1% a year for the price and +8.9% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Moderate durability comes from tablet sales momentum and long-term Catalent supply deals that secure capacity without patent cliffs, yet sparse public data and the costs of scaling production limit clearer assessment.
Main risk: The need to fund and ramp production capacity for sublingual tablets risks weighing on margins if investments outpace sustained demand growth.
ALK has upgraded its 2026 outlook on broad momentum in tablet sales. The expanded long-term supply deal with Catalent secures scaled capacity for its sublingual tablets into the 2030s and highlights a core business model with no patent cliff. Will sustained tablet demand keep lifting results or will the need to fund and ramp production start to weigh on margins?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 603 stocks
Beats the industry median on 8/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score77 · Top 25%
Fair Value upside+5.5% · Top 25%
Profitability
Return on equity (12 months)21.2% · Top 25%
Return on assets13.1% · Top 25%
Net margin (12 months)19.9% · Above median
Operating margin (12 months)24.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)17.6% · Above median
Dividend yield (12 months)0.7% · Below median
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "ALK-Abelló A/S Fair Value". https://www.fairvalue-calculator.com/stock/ALK-B
Frequently asked questions
Is ALK-Abelló A/S (ALK-B) overvalued or undervalued?
As of Oct 14, 2026, our model estimates a fair value of kr 249.92 versus a price of kr 237.80, about +5% upside (fairly valued).
What is the fair value of ALK-B?
Our model-based fair value for ALK-Abelló A/S is kr 249.92 (as of Oct 14, 2026), built from audited fundamentals. The current price: kr 237.80.
What is the quality score of ALK-B?
ALK-Abelló A/S has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ALK-Abelló A/S (ALK-B)?
Our model-based price target is the fair value of kr 249.92 (as of Oct 14, 2026) from 26 valuation models. Cautious scenario kr 183.75, optimistic scenario kr 312.40. It is a calculation from audited fundamentals, not an analyst target.
What is the ALK-Abelló A/S stock forecast for 2026?
Our models put fair value at kr 249.92, about +5% upside versus a price of kr 237.80 (fairly valued). Cautious scenario kr 183.75, optimistic scenario kr 312.40. The calculation is refreshed regularly with new filings.
What is the revenue of ALK-Abelló A/S (ALK-B)?
ALK-Abelló A/S reported trailing-twelve-month revenue of about 6.8B DKK (latest available figure, as of Oct 14, 2026).
Does ALK-Abelló A/S pay a dividend?
ALK-Abelló A/S currently shows a dividend yield of 0.67% relative to its recent price (as of Oct 14, 2026).
What growth is priced into ALK-Abelló A/S (ALK-B)?
For today's price to be fair in a discounted-cash-flow model, ALK-Abelló A/S would have to grow free cash flow by +16.5 % per year for five years (discount rate 8.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.6 % per year. As of Oct 14, 2026.
What discount rate (WACC) does the fair value of ALK-B use?
Our models discount ALK-Abelló A/S at 8.8 %: a base by market capitalisation (mid), damped by beta 0.70, country premium for Denmark. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ALK-Abelló A/S that is +16.5 % per year a year over ten years, using the same discount rate (8.8 %) and the same formula as our fair value.
How much growth has ALK-Abelló A/S (ALK-B) delivered so far?
Over the past 5 years revenue at ALK-Abelló A/S grew +12.6 % a year. The price currently implies +16.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ALK-Abelló A/S (ALK-B) growing?
The median revenue growth in the sector is +5.6 % a year. That is the yardstick for the growth priced into ALK-Abelló A/S (+16.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ALK-Abelló A/S (ALK-B)?
The free-cash-flow yield on the price is 2.92 %: that much free cash flow ALK-Abelló A/S produces per unit of market value. When it exceeds the discount rate of our models (8.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ALK-Abelló A/S (ALK-B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ALK-Abelló A/S it is kr 249.92 per share (as of Oct 14, 2026), against a price of kr 237.80. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is ALK-Abelló A/S stock overvalued or undervalued in 2026?
As of Oct 14, 2026, ALK-B trades below its calculated fair value: price kr 237.80, fair value kr 249.92, a gap of about +5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALK-B?
No. The price is what the market pays today (kr 237.80); the fair value is what the company's own numbers justify (kr 249.92). For ALK-Abelló A/S the two are kr 12.12 per share apart. That gap is exactly why we show both numbers side by side.
How much is ALK-Abelló A/S worth?
The market values ALK-Abelló A/S at about 52.8B DKK (market capitalisation, as of Oct 14, 2026). Per share that is kr 237.80; our models calculate a fair value of kr 249.92 per share.
What do the bullish and bearish scenarios say about ALK-B?
Our models span a range for ALK-Abelló A/S: cautious scenario kr 183.75, base kr 249.92, optimistic kr 312.40 per share (as of Oct 14, 2026, price kr 237.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALK-B?
ALK-Abelló A/S trades at a price-to-earnings ratio of 32.8 (as of Oct 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 249.92 is built from several models across several years. Other multiples: PEG 9.9, P/B 8.2, P/S 7.7, EV/EBITDA 24.6.
What is the PEG ratio of ALK-B?
The PEG ratio of ALK-Abelló A/S is 9.87 (P/E divided by earnings growth, as of Oct 14, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of ALK-Abelló A/S (ALK-B)?
Balance-sheet figures for ALK-Abelló A/S (as of Oct 14, 2026): return on equity 21.2%, debt of 0.02 per unit of equity. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is ALK-B from its 52-week high?
ALK-Abelló A/S trades at kr 237.80, about 12% below its 52-week high of kr 270.40 and 24% above the low of kr 192.30 (as of Oct 20, 2026). Distance from the high says nothing about value: that is what the fair value of kr 249.92 is for.
Which stocks are comparable to ALK-Abelló A/S?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ALK-Abelló A/S stock attractive at the current price?
The data as of Oct 14, 2026: price kr 237.80, calculated fair value kr 249.92 (+5%), Quality Score 77/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALK-B calculated?
We run ALK-Abelló A/S through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 249.92, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. ALK-Abelló A/S currently trades 5 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ALK-Abelló A/S (ALK-B)?
The closing price on Oct 20, 2026 was kr 237.80. Our model-based fair value is kr 249.92, about +5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ALK-Abelló A/S right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of ALK-Abelló A/S (ALK-B) come from?
Earnings per share at ALK-Abelló A/S grew +12.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.1 %, EBIT margin +5.3 %, tax rate +1.2 %, residual (interest, one-offs) −1.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of ALK-Abelló A/S
How large is the market capitalisation of ALK-Abelló A/S (ALK-B)?
The market capitalisation of ALK-Abelló A/S is 52.8B DKK (≈ $7.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ALK-Abelló A/S (ALK-B)?
The price-to-sales ratio of ALK-Abelló A/S is 7.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ALK-Abelló A/S (ALK-B)?
Earnings per share at ALK-Abelló A/S are kr 6.09 (price ÷ EPS = P/E 32.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of ALK-Abelló A/S (ALK-B)?
The dividend yield of ALK-Abelló A/S is 0.7% (payout 26.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of ALK-Abelló A/S (ALK-B)?
The net margin of ALK-Abelló A/S is 19.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ALK-Abelló A/S (ALK-B)?
The return on equity (ROE) of ALK-Abelló A/S is 21.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ALK-Abelló A/S (ALK-B)?
On an EBIT basis the return on assets of ALK-Abelló A/S is 10.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ALK-Abelló A/S (ALK-B)?
The operating margin of ALK-Abelló A/S is 24.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ALK-Abelló A/S (ALK-B)?
Revenue at ALK-Abelló A/S is growing +17.6% versus a year earlier (3y avg +11.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ALK-Abelló A/S (ALK-B)?
Earnings per share at ALK-Abelló A/S are growing +25.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does ALK-Abelló A/S (ALK-B) hold?
ALK-Abelló A/S holds more cash than debt, 618M DKK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch ALK-Abelló A/S in the live analysis
One click puts ALK-Abelló A/S on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 14, 2026